Brief: Sprint Bioscience Q3 Operating Result Turns To Loss
30/10/2024 06:39
Oct 30 (Reuters) - Sprint Bioscience AB SPRINT.ST :
* Q3 NET SALES SEK 14.8 MILLION VERSUS SEK 39.6 MILLION YEAR
AGO
* Q3 OPERATING LOSS SEK 5.4 MILLION VERSUS PROFIT SEK 28.4
MILLION
YEAR AGO
Source text: ID:nMFNb1Kyw2
Further company coverage: SPRINT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Sprint Bioscience AB
See all newsBrief: Sprint Bioscience And Max IV Receive Funding From Vinnova
Brief: Sprint Bioscience Q2 Loss After Tax SEK 16.2 Million
Brief: Sprint Bioscience Announces Deal With Lilly Tunelab
Brief: Sprint Bioscience Partners With Lilly Tunelab For Drug Development
Brief: Sprint Bioscience Q1 Operating Loss SEK 14.3 Mln